Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

```
Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:30:48 ON 30 JUL 2008

=> file registry
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.42       0.42

FILE 'REGISTRY' ENTERED AT 10:32:07 ON 30 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JUL 2008  HIGHEST RN 1036977-72-6
DICTIONARY FILE UPDATES:  29 JUL 2008  HIGHEST RN 1036977-72-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp beclamethasone dipropionate/cn
E1            1     BECKURANE M118/CN
E2            1     BECLACIN/CN
E3            0 --> BECLAMETHASONE DIPROPIONATE/CN
E4            1     BECLAMID/CN
E5            1     BECLAMIDE/CN
E6            1     BECLATE/CN
E7            1     BECLAZONE/CN
E8            1     BECLAZONE 250/CN
E9            1     BECLAZONE 50/CN
E10           1     BECLICONAZOLE/CN
E11           1     BECLIN (HUMAN BRAIN BCL-2-INTERACTING PROTEIN)/CN
E12           1     BECLIN (HUMAN CLONE 1259)/CN

=> exp beclomethasone dipropionate/cn
E1            1     BECLOMETHASONE 21-PROPIONATE/CN
E2            1     BECLOMETHASONE DIPENTANOATE/CN
E3            1 --> BECLOMETHASONE DIPROPIONATE/CN
```

```
E4            1     BECLOMETHASONE DIPROPIONATE COMPD. WITH ETHANOL (1:2)/CN
E5            1     BECLOMETHASONE DIPROPIONATE ETHYLACETATE SOLVATE/CN
E6            1     BECLOMETHASONE DIPROPIONATE MONOHYDRATE/CN
E7            1     BECLOMETHASONE DIVALERATE/CN
E8            1     BECLOMETHASONE-FREON 11 CLATHRATE/CN
E9            1     BECLOMETHASONE-PROPELLANT 11 CLATHRATE/CN
E10           1     BECLOTHIAMINE NAPHTHALENE-1,5-DISULFONATE/CN
E11           1     BECLOTIAMINE/CN
E12           1     BECLOTIAMINE NAPADISYLATE/CN

=> s E3-E6
              1 "BECLOMETHASONE DIPROPIONATE"/CN
              1 "BECLOMETHASONE DIPROPIONATE COMPD. WITH ETHANOL (1:2)"/CN
              1 "BECLOMETHASONE DIPROPIONATE ETHYLACETATE SOLVATE"/CN
              1 "BECLOMETHASONE DIPROPIONATE MONOHYDRATE"/CN
L1            4 ("BECLOMETHASONE DIPROPIONATE"/CN OR "BECLOMETHASONE DIPROPIONAT
                E COMPD. WITH ETHANOL (1:2)"/CN OR "BECLOMETHASONE DIPROPIONATE
                ETHYLACETATE SOLVATE"/CN OR "BECLOMETHASONE DIPROPIONATE MONOHYD
                RATE"/CN)

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              21.06      21.48

FILE 'HCAPLUS' ENTERED AT 10:32:47 ON 30 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Jul 2008  VOL 149 ISS 5
FILE LAST UPDATED: 29 Jul 2008  (20080729/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l1/thu
          1299 L1
       1033106 THU/RL
L2          928 L1/THU
                (L1 (L) THU/RL)

=> s GVHD or HVGD or (graft-versus host) or (host-versus-graft) or transplant
          3290 GVHD
            15 HVGD
        113471 GRAFT
```

```
         36458 VERSUS
        237780 HOST
          2111 GRAFT-VERSUS HOST
                 (GRAFT(W)VERSUS(W)HOST)
        237780 HOST
         36458 VERSUS
        113471 GRAFT
            35 HOST-VERSUS-GRAFT
                 (HOST(W)VERSUS(W)GRAFT)
         70492 TRANSPLANT
L3       71185 GVHD OR HVGD OR (GRAFT-VERSUS HOST) OR (HOST-VERSUS-GRAFT) OR
               TRANSPLANT

=> s (long-term) or chronic or schedule
        862627 LONG
        367259 TERM
        204968 LONG-TERM
                 (LONG(W)TERM)
        243045 CHRONIC
         24646 SCHEDULE
L4      455955 (LONG-TERM) OR CHRONIC OR SCHEDULE

=> s l2 and l3
L5          31 L2 AND L3

=> s l5 and (PY<2001 or AY<2001 or PRY<2001)
      20984876 PY<2001
       3937740 AY<2001
       3406863 PRY<2001
L6            7 L5 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> d his


     (FILE 'HOME' ENTERED AT 10:30:48 ON 30 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 10:32:07 ON 30 JUL 2008
                EXP BECLAMETHASONE DIPROPIONATE/CN
                EXP BECLOMETHASONE DIPROPIONATE/CN
L1            4 S E3-E6

     FILE 'HCAPLUS' ENTERED AT 10:32:47 ON 30 JUL 2008
L2          928 S L1/THU
L3        71185 S GVHD OR HVGD OR (GRAFT-VERSUS HOST) OR (HOST-VERSUS-GRAFT) OR
L4       455955 S (LONG-TERM) OR CHRONIC OR SCHEDULE
L5           31 S L2 AND L3
L6            7 S L5 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> d l6 1-7 ti abs bib

L6   ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Preparation of nicotinamides and mimetics as inhibitors of
     phosphodiesterase IV isozymes
GI
```



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R8, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepared (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aqueous NaOH was added to the suspension, and the reaction mixture was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

AN 2002:591707 HCAPLUS

DN 137:140509

TI Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes

IN Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 1229034	A1	20020807	EP 2002-250202	20020111	
	EP 1229034	B1	20050413			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	AT 293109	T	20050415	AT 2002-250202	20020111	
	ES 2239203	T3	20050916	ES 2002-250202	20020111	
	CA 2369462	A1	20020731	CA 2002-2369462	20020129	
	MX 2002PA01141	A	20020918	MX 2002-PA1141	20020130	
	US 20020111495	A1	20020815	US 2002-62811	20020131	<--
	JP 2002284766	A	20021003	JP 2002-22710	20020131	
	BR 2002000250	A	20021008	BR 2002-250	20020131	
	US 20040171798	A1	20040902	US 2004-781062	20040217	
	US 7250518	B2	20070731			
PRAI	US 2001-265240P	P	20010131			
	US 1997-43403P	P	19970404	<--		
	US 1998-105120P	P	19981021	<--		
	US 2002-62811	B1	20020131			

OS MARPAT 137:140509

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method of long-term treatment of graft-versus-host disease using topical active corticosteroids

AB A method for long-term therapy using corticosteroids to treat tissue damage associated with graft-vs.-host disease in a patient having undergone hematopoietic cell transplantation, and host-vs.-graft disease in a patient having undergone organ allograft transplantation. The method includes orally administering to the patient a therapeutically effective amount of a topically active corticosteroid, such as beclomethasone dipropionate, from the 29th day until the 56th day following hematopoietic cell or organ allograft transplantation. Representative tissues includes tissue of the intestine and liver, while representative tissue damage includes inflammation thereof.

AN 2002:505407 HCAPLUS

DN 137:42096

TI Method of long-term treatment of graft-versus-host disease using topical active corticosteroids

IN McDonald, George B.; Stergiopoulos, Nicholas

PA USA

SO U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20020086857	A1	20020704	US 2001-753814	20010103 <--
US 20040006053	A1	20040108	US 2003-613788	20030703 <--
PRAI US 2000-233194P	P	20000915	<--	
US 2001-753814	B1	20010103		

L6 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of 1,3-bis-(substituted-phenyl)-2-propen-1-ones as VCAM-1 inhibitors for treatment of inflammatory disorders

GI



I



II

AB Title compds. I [wherein R2a, R3a, R4a, R5a, R6a, R2b, R3b, R4b, R5b, and R6b = independently H, (cyclo)alkyl, (hetero)aryl, carbocyclyl, (halo)alkylthio, (un)substituted alkoxy or amino, (halo)acyl, amido, (halo)alkylsulfonyl, aminocarbonyl, alkenyl, alkynyl, halo, OH, SH, CN, NO2, SO3H, sulf(on)amido, PO3H2, alditol, carbohydrate, amino acid, etc.; R22 and R23 = independently H or alkyl; or R22 and R6a or R23 and R6a can join together to form a bridged carbocycle, (hetero)aryl, or heterocycle; R2a and R3a, R3a and R4a, R4a and R5a, R5a and R6a, R2b and R3b, R3b and R4b, R4b and R5b, or R5b and R6b and independently join to form a bridged (un)substituted carbocycle, cycloalkenyl, cycloalk(en)ylcarbonyl, (hetero)aryl, heterocycle, or alkylenedioxy; and the E or Z isomers thereof] were prepared to inhibit the expression of VCAM-1. For example, 3',5'-dimethoxy-4'-hydroxyacetophenone was treated with Et glycolate, PPh3, and di-Et azodicarboxylate in THF to give 4'-ethoxycarbonylmethoxy-3',5'-dimethoxyacetophenone (90%). Coupling the acetophenone and 5-(benzo[b]thien-2-yl)-2,4-dimethoxybenzaldehyde (preparation given) in the presence of NaOH in absolute EtOH afforded the 1,3-diphenyl-2-propen-1-one II (39%), which stimulated cultured human aortic smooth muscle cell activity with IC50 of 0.45 μM. I are useful for the treatment of inflammatory disorders that are mediated by VCAM-1, including arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

AN 2001:935594 HCAPLUS
DN 136:69730

TI Preparation of 1,3-bis-(substituted-phenyl)-2-propen-1-ones as VCAM-1 inhibitors for treatment of inflammatory disorders

IN Meng, Charles Q.; Ni, Liming; Sikorski, James A.; Hoong, Lee K.
PA Atherogenics, Inc., USA

SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098291	A2	20011227	WO 2001-US19720	20010620 <--
	WO 2001098291	A3	20020516		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2413878	A1	20011227	CA 2001-2413878	20010620 <--
	BR 2001011889	A	20030624	BR 2001-11889	20010620 <--
	EP 1330448	A2	20030730	EP 2001-946583	20010620 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 6608101	B1	20030819	US 2001-886348	20010620 <--
	JP 2004501147	T	20040115	JP 2002-504247	20010620 <--
	NZ 523443	A	20041126	NZ 2001-523443	20010620 <--
	MX 2002PA12660	A	20040514	MX 2002-PA12660	20021218 <--
	IN 2003DN00008	A	20060609	IN 2003-DN8	20030101 <--
	ZA 2003000134	A	20051006	ZA 2003-134	20030106 <--

```
     US 20030236298         A1    20031225    US 2003-443470          20030521 <--
     US 7078431             B2    20060718
     US 20060258735         A1    20061116    US 2006-485940          20060713 <--
PRAI US 2000-212769P        P     20000620  <--
     US 2000-255934P        P     20001215  <--
     US 2001-886348         A1    20010620
     WO 2001-US19720        W     20010620
     US 2003-443470         A1    20030521
OS   MARPAT 136:69730

L6   ANSWER 4 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Method using oral administration of a topically active corticosteroid for
     preventing tissue damage associated with graft-versus-
     host or host-versus-graft disease
     following transplantation
AB   A method is provided for preventing tissue damage associated with
     graft-vs.-host disease in a patient having undergone hematopoietic cell
     transplantation, and host-vs.-graft disease in a patient having undergone
     organ allograft transplantation.  The method includes orally administering
     to the patient a prophylactically effective amount of a topically active
     corticosteroid, such as beclomethasone dipropionate, for a period of time
     following hematopoietic cell or organ allograft transplantation, and prior
     to the presentation of symptoms associated with graft-vs.-host disease or
     host-vs.-graft disease.  Representative tissues includes tissue of the
     intestine and liver, while representative tissue damage includes
     inflammation thereof.
AN   2000:531659  HCAPLUS
DN   133:115533
TI   Method using oral administration of a topically active corticosteroid for
     preventing tissue damage associated with graft-versus-
     host or host-versus-graft disease
     following transplantation
IN   McDonald, George B.
PA   Institute for Drug Research, Inc., USA
SO   U.S., 5 pp., Cont.-in-part of U.S. Ser. No. 103,762.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    -------------------     --------
PI   US 6096731           A      20000801    US 1998-151388          19980910 <--
     CA 2413883           A1     20011129    CA 2000-2413883         20000522 <--
     WO 2001089529        A1     20011129    WO 2000-US14064         20000522 <--
          W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 1998-103762      A2     19980624  <--
     US 1998-151388      A      19980910  <--
     WO 2000-US14064     W      20000522  <--
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 5 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Method and means for treating glomerulonephritis using glucocorticoids
     having a first pass metabolism in the liver
```

AB The invention provides the use of a glucocorticoid having a first pass metabolism in the liver of at least 90 % as active substance, for the manufacturing of a medicament for oral or rectal administration in the treatment of glomerulonephritis by releasing the active substance in the intestine. The invention also provides a method for treatment of glomerulonephritis in a native kidney or a kidney transplant with the glucocorticoid as defined above. The invention also comprises a composition comprising the active substance and a pharmaceutically acceptable carrier, adjuvant or diluent designed for oral or rectal administration.

AN 1999:613669 HCAPLUS

DN 131:223969

TI Method and means for treating glomerulonephritis using glucocorticoids having a first pass metabolism in the liver

IN Hallgren, Roger; Fellstrom, Bengt

PA Pharmalink Baslakemedel AB, Swed.

SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9947144	A1	19990923	WO 1999-SE406	19990316	<--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	SE 9800905	A	19990918	SE 1998-905	19980317	<--
	SE 514128	C2	20010108			
	US 6239120	B1	20010529	US 1999-266023	19990311	<--
	CA 2317796	A1	19990923	CA 1999-2317796	19990316	<--
	AU 9929686	A	19991011	AU 1999-29686	19990316	<--
	AU 749199	B2	20020620			
	EP 1056461	A1	20001206	EP 1999-910932	19990316	<--
	EP 1056461	B1	20020918			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	BR 9908838	A	20001212	BR 1999-8838	19990316	<--
	JP 2002506824	T	20020305	JP 2000-536384	19990316	<--
	AT 224195	T	20021015	AT 1999-910932	19990316	<--
	ES 2181407	T3	20030216	ES 1999-910932	19990316	<--
PRAI	SE 1998-905	A	19980317	<--		
	US 1998-80274P	P	19980401	<--		
	WO 1999-SE406	W	19990316	<--		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Oral beclomethasone dipropionate for treatment of intestinal graft -versus-host disease: a randomized, controlled trial

AB Beclomethasone dipropionate (BDP), a topically active steroid, seemed to be an effective treatment for intestinal graft-vs.-host disease (GVHD) in a phase I study. The aim of this study was to compare the effectiveness of oral BDP to that of placebo capsules in treatment of intestinal GVHD. Sixty patients with anorexia and poor oral intake because of intestinal GVHD were randomized to receive prednisone (1 mg · kg-1 · day-1) plus either oral BDP (8

mg/day) or placebo capsules. Initial responders who were eating at least 70% of caloric needs at evaluation on day 10 continued to take study capsules for an addnl. 20 days while the prednisone dose was rapidly tapered. The primary end point was the frequency of a durable treatment response at day 30 of treatment. The initial treatment response at day 10 was 22 of 31 (71%) in the BDP/prednisone group vs. 16 of 29 (55%) for the placebo/prednisone group. The durable treatment response at day 30 was 22 of 31 (71%) vs. 12 of 29 (41%), resp. (P = 0.02). The combination of oral BDP capsules and prednisone was more effective than prednisone alone in treating intestinal GVHD. Oral BDP allowed prednisone doses to be rapidly tapered without recurrent intestinal symptoms.

AN 1998:450133 HCAPLUS
DN 129:198161
OREF 129:40103a,40106a
TI Oral beclomethasone dipropionate for treatment of intestinal graft -versus-host disease: a randomized, controlled trial
AU Mcdonald, George B.; Bouvier, Michelle; Hockenbery, David M.; Stern, Jean M.; Gooley, Ted; Farrand, Allen; Murakami, Carol; Levine, Douglas S.
CS Gastroenterology/Hepatology, Clinical Statistics, and Clinical Nutrition Sections, Division of Clinical Research, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA, USA
SO Gastroenterology (1998), 115(1), 28-35
CODEN: GASTAB; ISSN: 0016-5085
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease
AB Oral beclomethasone dipropionate (BDP), a potent, topically active corticosteroid, was investigated as therapy for the title disease. Allogeneic marrow-graft recipients with biopsy-proven intestinal graft-vs.-host disease of mild-to-moderate severity received BDP (8 mg daily) for ≤28 days. Improvement was seen in appetite, oral food intake, nausea, and diarrhea over the course of therapy, and an overall beneficial response was observed in 72% of 40 evaluable patients. Surveillance cultures of throat and stools showed no increase in bacterial or fungal colonization over time. The adrenal axis became suppressed in 11 of 20 evaluable patients (55%) but suppression was not a prerequisite for clin. response, as 6 of 9 patients who retained normal adrenal function improved clin. It is concluded that oral BDP is a safe and effective treatment for mild-to-moderate intestinal graft-vs.-host disease. Systemic absorption probably occurs, but adrenal suppression is not a prerequisite for clin. efficacy, suggesting that the biol. effect is primarily topical.
AN 1996:49517 HCAPLUS
DN 124:165529
OREF 124:30435a,30438a
TI Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease
AU Baehr, Paul H.; Levine, Douglas S.; Bouvier, Michelle E.; Hockenbery, David M.; Gooley, Ted A.; Stern, Jean G.; Martin, Paul J.; McDonald, George B.
CS Clinical Research Division of the Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
SO Transplantation (1995), 60(11), 1231-8
CODEN: TRPLAU; ISSN: 0041-1337
PB Williams & Wilkins
DT Journal

LA English

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.75	47.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.60	-5.60

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:34:00 ON 30 JUL 2008